Back to search

Article

Effect of felzartamab anti-CD38 treatment on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies.

2024-08-16

Abstract excerpt

<title>Abstract</title> <p>A recent randomized controlled trial demonstrated that treatment with CD38 monoclonal antibody felzartamab suppressed antibody-mediated rejection (ABMR) in kidney transplant patients but with recurrence post-treatment in some patients. The present study examined the molecular effects of 6-months of felzartamab treatment on biopsies from the trial using genome-wide microarray analysis, c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
04a935e6-69a1-5c50-ba6e-ee3b0a0a2c95
DOI
10.21203/rs.3.rs-4870641/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Effect of felzartamab anti-CD38 treatment on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies.DOI 10.21203/rs.3.rs-4870641/v1
Select a neighboring publication to make it the new centre.